Helicobacter Pylori Non-invasive Testing Market by Test Type (Serology Test, Stool Antigen Test (SAT), Urea Breath Test (UBT)), Test Method (Laboratory based Tests and Point-of-Care Tests), End User (Hospitals, Clinics, Diagnostic Laboratories) - Global Analysis & Forecast 2019-2030
Report ID : 73 | Published Date : May 2019 | Pages : 150 | Region : Global | Report Code : MD-39
H. pylori non-invasive testing Market Overview and Introduction
The helicobacter pylori (H. pylori) non-invasive testing market was estimated to be over US$ 500 Mn in 2018. It is anticipated to grow at a 3.8% CAGR from 2019 to 2030.
Helicobacter pylori (H. pylori) is a bacteria that thrives in the digestive tract and can infest the stomach lining resulting in sores, also called as ulcers, over a period of time. This bacteria usually lining infects the lining of the stomach or the upper part of the small intestine. This infection can lead to peptic ulcers and gastritis. In certain cases this prolonged infection can lead to stomach cancer. In 1994, the WHO’s, International Agency for Research on Cancer classified H. pylori as a Class 1 carcinogen. As more parts of the world get access to clean water and sanitation, the prevalence of H. pylori will decrease. With good health habits and sanitation is possible to safeguard yourself against this infection.
The helicobacter pylori (H. pylori) non-invasive testing market is expected to be fueled by factors such as high prevalence rates of helicobacter pylori globally, noninvasive nature of these tests, which are user friendly as well. Some countries have prevalence rates that are higher than 80%. Although more than half the world’s population is infected by the helicobacter pylori bacteria infection the diagnosis rates remain low globally, mainly owing to its asymptomatic nature. This is expected to have an unfavorable effect on the growth of this market.
Helicobacter pylori (H. pylori) Market by Types
On the basis of test type the market is segmented into, serology test, stool antigen test (SAT) and urea breath test (UBT).The urea breath test segment is estimated to hold a substantial market share of the market, fueled by its growing ease of availability, ease of usage and accuracy of the test outcomes. Serology is anticipated to lose its market share, during the forecast period as it’s facing a ban by some of the regulatory bodies.
H. pylori non-invasive testing Market by Test Method
On basis of test method the market can be segmented into laboratory-based tests and point-of-care tests. The laboratory based tests are expected to hold the dominant share during the forecast, however the point of care expected to increase their existing market share owing to factors such being more patient-centric, less fragmented and its availability in remote locations.
H. pylori non-invasive testing Market by End Users
On the basis of end users the market is segmented into, hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories are expected to hold the maximum share, as the number of diagnostic labs is growing.
H. pylori non-invasive testing Market by Region
The global helicobacter pylori (H. pylori) non-invasive testing market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of helicobacter pylori (H. pylori) non-invasive testing. Rising awareness about the non-invasive testing options, rapid technological advancements in the field of helicobacter pylori (H. pylori) non-invasive testing. Relatively higher diagnosis rate of H. pylori infection in North America is further expected to fuel the market growth in this region. Europe is expected to hold the second most significant share of this market. Increasing patient pool that is intent on early diagnosis of helicobacter pylori infection to avoid peptic ulcers is expected to aid the growth of the market in the European region.
H. pylori non-invasive testing Market Prominent Players
The prominent players in the global helicobacter pylori (H. pylori) non-invasive testing market are Meridian Bioscience, Inc., DiaSorin S.p.A., Exalenz Bioscience Ltd., Thermo Fisher Scientific, Alere, Certest Biotec S.L, Sekisui Diagnostics, Biomerica, Inc, CorisBioconcept SPRL, and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. among others.